However, with the advent of molecular-targeted therapies, trastuzumab, a human epidermal growth factor receptor 2 (HER2) targeting monoclonal antibody (mAb), became the first-line treatment for HER2-positive GC [3]; moreover, as second-line treatment, ramucirumab, a vascular endothelial growth factor receptor 2-targeting mAb, also showed survival benefit when combined with paclitaxel [4]. The gene discussed is ERBB2; the disease is gastric cancer.